Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 406 participants.
Also called NCT05880056
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 406 participants
- Sponsor
- Genuine Research Center, Egypt
- Registry
-
NCT05880056
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Unknown status
Technical summary
Registry record NCT05880056. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-08 (actual); primary completion 2025-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
- Acronym
- BETTER
- Condition
- Essential Hypertension
- Intervention (Drug)
- Nerkardou (5 mg) & (10 mg)
- Lead sponsor
- Genuine Research Center, Egypt
- Collaborator
- Nerhadou International for pharmaceutical & Nutraceutical, Egypt
Record details
- Record id
cardio:ct-nct05880056- Content hash
705a5ee9f6aa85cf471049f33f6acf99414efb67bf1426103cb83eaea4e61a50